Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Xbrane enlists CR on Chinese ranibizumab

Executive Summary

Sweden’s Xbrane Biopharma plans to bring its biosimilar ranibizumab, Xlucane, to the Chinese market through a partnership with local firm CR Pharma, the companies have revealed following the signing of a “non-binding letter of intent”. Announcing the partnership, CR Pharma said it would be responsible for registering and marketing the biosimilar in China, as well as conducting any necessary clinical research.

You may also be interested in...

Xbrane Pauses Primm Divestment Process

Xbrane Biopharma has paused the process of divesting its Primm Pharma subsidiary, developer of the Spherotide long-acting triptorelin formulation, after failing to reach a final agreement with the expected acquirer, Italy’s NewFaDem.

Stada and Xbrane Add Two To Biosimilar Development Alliance

Stada and Xbrane have expanded their biosimilar development alliance by adding the Swedish firm’s certolizumab and nivolumab pre-clinical programs to the partnership.

Xbrane Expects Its Lucentis Rival To Capture A Quarter Of Volumes

Xbrane, which has just kicked off a Phase III study for its Xlucane ranibizumab biosimilar to Lucentis, has set a target of ranibizumab generating annual sales of €350m within three years of launch, based on capturing a quarter of the Lucentis market by volume in both Europe and the US.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts